<DOC>
	<DOCNO>NCT00932126</DOCNO>
	<brief_summary>This first study use PF-03758309 , oral compound , patient advance solid tumor . In study different dose PF-03758309 administered different group patient . The study ass compound 's safety , blood level PF-03758309 treatment effect compound tumor cell .</brief_summary>
	<brief_title>This Is The First Study Using Escalating Doses Of PF-03758309 , An Oral Compound , In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study prematurely terminate 26Jul2011 due undesirable PK characteristic PF-03758309 lack observe dose-response relationship . There safety concern contribute study termination .</detailed_description>
	<criteria>Advanced/metastatic solid tumor resistant standard therapy standard therapy available . ECOG ( Eastern Cooperative Oncology Group ) Performance Status ( PS ) must 0 1 . Adequate bone marrow , liver kidney function . Patients know brain metastasis . Previous high dose chemotherapy require stem cell rescue . Prior irradiation &gt; 25 % bone marrow . Active bacterial , fungal viral infection include hepatitis B ( HBV ) , hepatitis C ( HCV ) . Current active treatment another clinical study . Pregnancy breast feed . Active inflammatory gastrointestinal disease , chronic diarrhea ( unless relate underlying malignancy prior related treatment ) history abdominal fistula , gastrointestinal perforation , peptic ulcer disease , intraabdominal abscess within 6 month prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase 1 dose escalation dose find pharmacokinetic pharmacodynamic study</keyword>
</DOC>